Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics — Oct 3rd, 2024

Myriad Genetics, Inc. SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequen...

BMRN or MYGN: Which Is the Better Value Stock Right Now? — Oct 1st, 2024

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Myriad Genetics (MYGN). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. There are plenty of ...

Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date — Oct 1st, 2024

Myriad Genetics, Inc. SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability ...